ALX Oncology Holdings, Inc. (ALXO)

In the past six months, ALX Oncology's stock has experienced significant volatility. Key events include the pricing of an underwritten offering, presentations at the J.P. Morgan Healthcare Conference, reporting third-quarter 2025 financial results, and a stock plunge to a 52-week low. The company also announced FDA clearance for an Investigational New Drug application for ALX2004 and a strategic workforce reduction of approximately 30%. There were reports of insider buying, the resignation of its CMO, and stock purchases by the Chief Financial Officer. The company announced a workforce reduction of approximately 30% and the elimination of the President and Chief Scientific Officer role as part of a pipeline prioritization and cash preservation strategy. Insider trading activity in the last 24 months shows insiders purchased a total of 3,323,346 ALXO shares for over $5.2 million and sold 172,309 shares for over $1.8 million.

As a clinical-stage biopharmaceutical company, ALX Oncology's products are still in clinical trials and not yet commercially available, so there is no information indicating demand seasonality.

ALX Oncology is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. Its lead product candidate, Evorpacept, is in Phase 1 and 2 clinical trials as a combination therapy for various cancers. The company also has collaboration agreements for Evorpacept combination programs with partners such as Jazz Pharmaceuticals plc, Quantum Leap Healthcare collaborative, MD Anderson Cancer Center, Sanofi, and the University of Pittsburgh. Additionally, the company is advancing NX-1607, an oral small-molecule inhibitor of CBL-B, and ALX2004 for EGFR-expressing solid tumors.

ALX Oncology Holdings, Inc. is headquartered in South San Francisco, California, and primarily focuses on developing therapies for cancer patients in the United States.

ALX Oncology emphasizes its science-driven approach and commitment to advancing cancer therapies. However, significant drops in stock price, a strategic reorganization including workforce reduction, and discontinuation of evaluations for Evorpacept in certain cancers could have negatively impacted its reputation.

ALX Oncology Holdings Inc. has 88 institutional owners and shareholders holding a total of 28,317,994 shares. Major institutional owners include venBio Partners LLC, Redmile Group, LLC, Millennium Management Llc, Almitas Capital LLC, Vanguard Group Inc, Acadian Asset Management Llc, UBS Group AG, Driehaus Capital Management Llc, and Two Sigma Advisers, Lp. Institutional ownership accounts for approximately 64.15% of shares, while individuals hold about 2.97%. Insiders own 21.00% of ALX Oncology stock.